Johnson & Johnson Taiwan is advancing patient access, precision diagnosis, and coordinated care to support the Healthy Taiwan vision and help more patients benefit from innovation earlier.
Taiwan’s healthcare strengths, tech know-how, and investor support are driving a fast-growing MedTech ecosystem. Startups in digital health, AI diagnostics, and connected care are finding Taiwan an ideal gateway to Asia.
Johnson & Johnson Taiwan is advancing healthcare through groundbreaking innovations in medicine and MedTech, while championing faster access, patient-centered care, and workforce development. From oncology and neuroscience to AI-powered surgery, the company is redefining what’s possible in Taiwan’s evolving healthcare landscape.
Eli Lilly, a global leader in healthcare innovation, is tackling Taiwan’s healthcare challenges under the leadership of new general manager Lauren Lazowski. Through advanced clinical trials, precision medicine, and strong partnerships, Lilly Taiwan is committed to improving patient outcomes and strengthening the healthcare system.
Pancreatic cancer remains one of the deadliest cancers, but researchers at National Taiwan University Hospital have developed an AI-assisted model to detect small tumors with 80% sensitivity, offering hope for earlier diagnosis. Taiwan’s AI innovations in healthcare, supported by its universal healthcare system and robust medical data, are transforming cancer detection and treatment.
As Taiwan navigates the challenges of a super-aged population, GSK leads with innovative solutions, focusing on prevention and treatment. By uniting science, technology, and talent, the company aims to improve health outcomes for Taiwan and beyond.
Taiwan is intensifying efforts to combat cardiovascular disease, the nation’s second leading cause of death, through initiatives like the NHIA’s 888 Plan and telehealth innovations from iXensor. A focus on preventive care, early intervention, and expanded access to advanced treatments aims to improve outcomes and reduce healthcare burdens.
In September, Taiwan’s National Health Insurance Administration expanded coverage to 46 da Vinci robotic-assisted surgeries, benefiting 8,400 patients annually. Patients now only pay material copayments, adding NT$285 million (US$8.75 million) to the NHI budget. This change boosts healthcare efficiency and improves patient outcomes, with fewer complications and faster recoveries, making robotic-assisted surgery a cost-effective long-term solution despite initial costs.
Becton, Dickinson and Co. (BD) has evolved from a syringe manufacturer into a leading MedTech company, driving digital transformation in healthcare with solutions like automated pharmacy systems that improve efficiency and patient outcomes. In Taiwan, BD’s innovations align with the government’s “Healthy Taiwan” initiative, as the country aims to establish itself as a MedTech hub. Despite Taiwan’s strengths in electronics and healthcare, challenges such as improving software and aligning regulatory standards with global norms remain. As AI becomes integral to healthcare, addressing these issues will be crucial for Taiwan’s MedTech competitiveness.
